{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:14:44Z","timestamp":1791328484209,"version":"4.3.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T00:00:00Z","timestamp":1660003200000},"content-version":"vor","delay-in-days":373,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007320","name":"Albert Einstein Cancer Center","doi-asserted-by":"publisher","award":["P30 CA013330"],"award-info":[{"award-number":["P30 CA013330"]}],"id":[{"id":"10.13039\/100007320","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Cell"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.ccell.2021.06.002","type":"journal-article","created":{"date-parts":[[2021,6,5]],"date-time":"2021-06-05T13:18:37Z","timestamp":1622899117000},"page":"1081-1090.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":317,"title":["Seroconversion rates following COVID-19 vaccination among patients with cancer"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7778-0752","authenticated-orcid":false,"given":"Astha","family":"Thakkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus D.","family":"Gonzalez-Lugo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8104-7289","authenticated-orcid":false,"given":"Niyati","family":"Goradia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhika","family":"Gali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0138-8986","authenticated-orcid":false,"given":"Lauren C.","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kith","family":"Pradhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shafia","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4102-5880","authenticated-orcid":false,"given":"So Yeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7697-1239","authenticated-orcid":false,"given":"Brian","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8877-4470","authenticated-orcid":false,"given":"R. Alejandro","family":"Sica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah","family":"Kornblum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizamarie","family":"Bachier-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8385-915X","authenticated-orcid":false,"given":"Margaret","family":"McCort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Goel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Perez-Soler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Packer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9031-2010","authenticated-orcid":false,"given":"Joseph","family":"Sparano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Gartrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Della","family":"Makower","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6367-8335","authenticated-orcid":false,"given":"Yitz D.","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Wolgast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balazs","family":"Halmos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccell.2021.06.002_bib1","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2021.06.002_bib2","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.ccell.2020.09.018","article-title":"COVID-19 and cancer: current challenges and perspectives","volume":"38","author":"Bakouny","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2021.06.002_bib3","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-021-01386-7","article-title":"CD8+ T\u00a0cells contribute to survival in patients with COVID-19 and hematologic cancer","author":"Bange","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2021.06.002_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2021.04.019","article-title":"Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors","author":"Barri\u00e8re","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ccell.2021.06.002_bib5","doi-asserted-by":"crossref","first-page":"e389","DOI":"10.1016\/S2352-3026(21)00110-1","article-title":"Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma","volume":"8","author":"Bird","year":"2021","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.ccell.2021.06.002_bib6","article-title":"Anti-SARS-CoV-2 antibody levels are concordant across multiple platforms but are not fully predictive of sterilizing immunity","author":"Bradley","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.ccell.2021.06.002_bib7","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1034\/j.1600-065X.2003.00065.x","article-title":"Cell-cycle control of plasma cell differentiation and tumorigenesis","volume":"194","author":"Chen-Kiang","year":"2003","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ccell.2021.06.002_bib8","doi-asserted-by":"crossref","first-page":"E2950","DOI":"10.1073\/pnas.1720431115","article-title":"Cyclin-dependent kinase activity is required for type I interferon production","volume":"115","author":"Cing\u00f6z","year":"2018","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ccell.2021.06.002_bib9","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41571-021-00487-z","article-title":"COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials","volume":"18","author":"Desai","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ccell.2021.06.002_bib10","doi-asserted-by":"crossref","first-page":"e14245","DOI":"10.1111\/ctr.14245","article-title":"Bamlanivimab for treatment of COVID-19 in solid organ transplant recipients: early single-center experience","volume":"35","author":"Dhand","year":"2021","journal-title":"Clin. Transplant."},{"key":"10.1016\/j.ccell.2021.06.002_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2021.04.006","article-title":"Care without a compass: including patients with cancer in COVID-19 studies","author":"Friese","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2021.06.002_bib12","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13045-020-00970-7","article-title":"Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study","volume":"13","author":"Garc\u00eda-Su\u00e1rez","year":"2020","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.ccell.2021.06.002_bib13","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.annonc.2021.02.024","article-title":"Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium","volume":"32","author":"Grivas","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ccell.2021.06.002_bib14","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2021011568","article-title":"Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia","author":"Herishanu","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2021.06.002_bib15","doi-asserted-by":"crossref","first-page":"628","DOI":"10.3390\/v13040628","article-title":"Neutralizing antibody therapeutics for COVID-19","volume":"13","author":"Hurt","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.ccell.2021.06.002_bib16","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1182\/blood-2006-04-006981","article-title":"Immunogenicity of recombinant hepatitis B vaccine (rHBV) in recipients of unrelated or related allogeneic hematopoietic cell (HC) transplants","volume":"108","author":"Jaffe","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2021.06.002_bib17","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1200\/JCO.20.01307","article-title":"Chemotherapy and COVID-19 outcomes in patients with cancer","volume":"38","author":"Jee","year":"2020","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ccell.2021.06.002_bib18","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/cncr.30468","article-title":"Optimal timing of influenza vaccination during 3-week cytotoxic chemotherapy cycles","volume":"123","author":"Keam","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ccell.2021.06.002_bib19","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1056\/NEJMc2101667","article-title":"Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine","volume":"384","author":"Krammer","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2021.06.002_bib20","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(20)31187-9","article-title":"Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study","volume":"395","author":"Kuderer","year":"2020","journal-title":"The Lancet"},{"key":"10.1016\/j.ccell.2021.06.002_bib21","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3389\/fcell.2019.00023","article-title":"Immunomodulatory roles of cell cycle regulators","volume":"7","author":"Laphanuwat","year":"2019","journal-title":"Front. Cell. Dev. Biol."},{"key":"10.1016\/j.ccell.2021.06.002_bib22","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/S0140-6736(20)31173-9","article-title":"COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study","volume":"395","author":"Lee","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ccell.2021.06.002_bib23","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S1470-2045(20)30442-3","article-title":"COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study","volume":"21","author":"Lee","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ccell.2021.06.002_bib24","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.annonc.2020.10.473","article-title":"Seroconversion in patients with cancer and oncology health care workers infected by SARS-CoV-2","volume":"32","author":"Marra","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ccell.2021.06.002_bib25","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1158\/2159-8290.CD-20-0516","article-title":"Case fatality rate of cancer patients with COVID-19 in a New York hospital system","volume":"10","author":"Mehta","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2021.06.002_bib26","article-title":"Interim results of the safety and immune-efficacy of 1 versus 2 doses of COVID-19 vaccine BNT162b2 for cancer patients in the context of the UK vaccine priority guidelines","author":"Monin-Aldama","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.ccell.2021.06.002_bib27","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1136\/jclinpath-2020-206658","article-title":"Gene of the month: the 2019-nCoV\/SARS-CoV-2 novel coronavirus spike protein","volume":"73","author":"Pillay","year":"2020","journal-title":"J.\u00a0Clin. Pathol."},{"key":"10.1016\/j.ccell.2021.06.002_bib28","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1182\/blood.2020008758","article-title":"Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines","volume":"137","author":"Pleyer","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2021.06.002_bib29","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2021.06.002_bib30","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1158\/2159-8290.CD-20-1817","article-title":"Priority COVID-19 vaccination for patients with cancer while vaccine supply is limited","volume":"11","author":"Ribas","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2021.06.002_bib31","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.drudis.2020.11.025","article-title":"Expanded access programs, compassionate drug use, and emergency use authorizations during the COVID-19 pandemic","volume":"26","author":"Rizk","year":"2021","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ccell.2021.06.002_bib32","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/s41591-020-0979-0","article-title":"Determinants of COVID-19 disease severity in patients with cancer","volume":"26","author":"Robilotti","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2021.06.002_bib33","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/cid\/cit816","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ccell.2021.06.002_bib34","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and efficacy of single-dose Ad26.COV2.S vaccine against covid-19","author":"Sadoff","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2021.06.002_bib35","article-title":"Low neutralizing antibody responses against SARS-CoV-2 in elderly myeloma patients after the first BNT162b2 vaccine dose","author":"Terpos","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2021.06.002_bib36","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s43018-021-00191-y","article-title":"Patterns of seroconversion for SARS-CoV-2 IgG in patients with malignant disease and association with anticancer therapy","volume":"2","author":"Thakkar","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.ccell.2021.06.002_bib37","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41591-021-01240-w","article-title":"COVID-19 vaccination: the VOICE for patients with cancer","volume":"27","author":"Van Der Veldt","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2021.06.002_bib38","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1470-2045(21)00155-8","article-title":"Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors","volume":"22","author":"Waissengrin","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ccell.2021.06.002_bib39","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ccell.2020.09.007","article-title":"SARS-CoV-2 viral load predicts mortality in patients with and without cancer who are hospitalized with COVID-19","volume":"38","author":"Westblade","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2021.06.002_bib40","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1056\/NEJMc2032195","article-title":"Durability of responses after SARS-CoV-2 mRNA-1273 vaccination","volume":"384","author":"Widge","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2021.06.002_bib41","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1038\/s41467-020-18319-6","article-title":"Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor","volume":"11","author":"Yang","year":"2020","journal-title":"Nat. Commun."}],"container-title":["Cancer Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610821002853?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610821002853?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:07:06Z","timestamp":1761523626000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535610821002853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S1535610821002853"],"URL":"https:\/\/doi.org\/10.1016\/j.ccell.2021.06.002","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.05.07.21256824","asserted-by":"object"}]},"ISSN":["1535-6108"],"issn-type":[{"value":"1535-6108","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Seroconversion rates following COVID-19 vaccination among patients with cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccell.2021.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ccell.2021.06.009","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}